Use of recombinant factor VIII Advate in paediatric patients
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F09%3A00100632" target="_blank" >RIV/00843989:_____/09:00100632 - isvavai.cz</a>
Výsledek na webu
—
DOI - Digital Object Identifier
—
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Use of recombinant factor VIII Advate in paediatric patients
Popis výsledku v původním jazyce
Recombinant products represent unambiguous technological progress, and are very likely to increase the safety of haemophilia treatment. It is evidenced by their growing consumption, particularly in paediatric patients, in all developed countries which have recommended recombinant products as the treatment of choice. The higher incidence of the inhibitor reported in some publications has not been fully confirmed till this time, and, in addition, the 3rd generation recombinant products appear to be less immunogenic compared to products of previous generations. The lower volume of the product after dissolution is also advantageous for paediatric use.Our limited experience in the treatment with rFVIII Advate is very good, and we are going to struggle to include the recombinant products among fully reimbursed routine treatment of haemophilia.
Název v anglickém jazyce
Use of recombinant factor VIII Advate in paediatric patients
Popis výsledku anglicky
Recombinant products represent unambiguous technological progress, and are very likely to increase the safety of haemophilia treatment. It is evidenced by their growing consumption, particularly in paediatric patients, in all developed countries which have recommended recombinant products as the treatment of choice. The higher incidence of the inhibitor reported in some publications has not been fully confirmed till this time, and, in addition, the 3rd generation recombinant products appear to be less immunogenic compared to products of previous generations. The lower volume of the product after dissolution is also advantageous for paediatric use.Our limited experience in the treatment with rFVIII Advate is very good, and we are going to struggle to include the recombinant products among fully reimbursed routine treatment of haemophilia.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FG - Pediatrie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
Z - Vyzkumny zamer (s odkazem do CEZ)
Ostatní
Rok uplatnění
2009
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Hämostaseologie
ISSN
0720-9355
e-ISSN
—
Svazek periodika
29
Číslo periodika v rámci svazku
Suppl.1
Stát vydavatele periodika
DE - Spolková republika Německo
Počet stran výsledku
3
Strana od-do
—
Kód UT WoS článku
000272214600014
EID výsledku v databázi Scopus
—